NPR2
Atrial natriuretic peptide receptor 2
As of the edition of 20 October 2026, NPR2 (atrial natriuretic peptide receptor 2, UniProt P20594) has 3 drugs tested at it and 4 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20594
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Inherited and neonatal; Bones, joints and muscles; Hormones; Heart and blood vessels; Skin and connective tissue; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vosoritide | Marketed | Phase 3 | Ends 2035 |
| Navepegritide | Marketed | Phase 3 | Ends 2037 |
| Carperitide | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Amicus Therapeutics | Route B |
| Ascendis Pharma A/S | Route B |
| Daiichi Sankyo | Route A |
The other 1 company at NPR2
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at NPR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.